研究人员针对 G 蛋白偶联受体（GPCR）药物研发难题，研究神经降压素受体 1（NTSR1）与 β-arrestin1 及变构调节剂 SBI-553 复合物结构，揭示独特 “环结合” 构型，推动 GPCR 靶向疗法发展。 研究背景：GPCR 药物研发的困境与机遇 在生命科学的微观世界里，G 蛋白偶联 ...

3月14日，山东大学基础医学院孙金鹏教授团队，联合北京大学医学部基础医学院姜长涛教授和孔炜教授团队、山东大学于晓教授团队，在《科学》(Science)在线发表研究论文“Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis”。 该研究首次发现了脂肪细胞中的神经酰胺膜受体F ...

3月14日，山东大学基础医学院孙金鹏教授团队，联合北京大学医学部基础医学院姜长涛教授和孔炜教授团队、山东大学于晓教授团队，在《科学》(Science)在线发表研究论文“Metabolic signaling of ceramides through ...

STRASBOURG, France; MONTREAL, Canada; BOSTON, MA, USA I March 20, 2025 I Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep ...

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for ...

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected ...

Cambridge biotech Maxion Therapeutics has raised $72 million (£58m) in a Series A financing to further grow the business ...

新华社客户端济南3月15日电（马传顺）山东大学基础医学院孙金鹏教授团队联合北京大学医学部基础医学院姜长涛教授和孔炜教授团队、山东大学于晓教授团队3月14日在《科学》(Science)在线发表研究论文“Metabolic signaling of ceramides through the FPR2 receptor inhibits adipocyte thermogenesis”。 该研究首次发 ...

Maxion Therapeutics Ltd. has raised $72 million (£58 million) in a series A financing to support its development of antibody-based Knotbody drugs for ion channel- and G protein-coupled receptor (GPCR) ...